CVRx, Inc. announced on October 18, 2024, that the American Medical Association (AMA) CPT Editorial Panel accepted new Current Procedural Terminology (CPT) Category I codes for its Barostim therapy. These codes are specifically for treating the symptoms of heart failure and are expected to be implemented on January 1, 2026.
This decision was made in response to the increased utilization of Barostim therapy and the strong evidence supporting its clinical outcomes. The transition from Category III to Category I codes is anticipated to further facilitate reimbursement for healthcare providers performing the Barostim procedure.
Kevin Hykes, CEO of CVRx, stated that the Category I code designation represents an important milestone for the company. It is a testament to the increased adoption, safety, and effectiveness of Barostim as a treatment option for patients suffering from debilitating heart failure symptoms, and is expected to enable broader patient access.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.